BGI Group
Scroll down to explore↓
A Fresh Start
In 2023, BGI Group inaugurated the BGI Center, its new global headquarters located in Shenzhen. This milestone signifies BGI’s more than two decades of dedication for life sciences, and its commitment to "Omics for All."
Key Technologies for Scientific Research
BGI Group has developed beyond the phase of participating and excelling, achieving comprehensive leadership in certain areas of life sciences by focusing on the forefront of basic research and key challenges. The group strives to realize significant technological breakthroughs and to develop cutting-edge technologies. In 2023, the DCS Lab Global Scientific Research Empowerment Program was officially launched. Laboratories have been established or are slated for establishment in Chinese cities such as Hangzhou, as well as in international cities including Brisbane, Australia.

STOmics Technology
In 2023, BGI launched a series of cutting-edge products, such as the Spatiotemporal Cloud Platform, mIF+ Transcriptome, and H&E+ Transcriptome, which have significantly reduced the costs of undertaking high-resolution spatiotemporal research on a single sample. These innovations have created a comprehensive spatiotemporal ecosystem that empowers scientific research across various fields. Currently, BGI's STOmics technology is assisting numerous universities and research institutions around the world to conduct research in diverse areas, including organ regeneration, embryonic development, brain science, cancer, and more.

0.5cm × 0.5cm STOmics Chip
A Leader in Scientific Research
BGI has upheld its leading position in the 2023 Nature Index ranking as the foremost corporate institution for biological sciences research in the Asia Pacific region for the eighth consecutive year. Additionally, four distinguished BGI researchers have been included in Clarivate Analytics' Highly Cited Researchers list for 2023, the ninth consecutive year for BGI.

Research Achievements
In 2023, BGI achieved multiple breakthroughs in research fields such as brain science, disease, zoology, botany, evolution, and development. This year, BGI has published a total of 382 papers, including 62 articles in CNNS journals (Nature and its subsidiary journals, Science and its subsidiary journals, Cell and its subsidiary journals, and the New England Journal of Medicine ).

To date, BGI has published a total of 4,892 papers, including 569 articles in CNNS journals, 15 articles in the main journal.

In March, research on the Antarctic krill genome was featured as a cover story in Cell. The study uncovered how Antarctic krill adapt to their environment and provided insights into their population dynamics. As one of the most abundant multicellular species, Antarctic krill are crucial to marine ecosystems. The findings offer a theoretical foundation for future research and practical resource utilization, which is vital for preserving krill habitats and the marine life that relies on them.


In June, researchers at BGI identified a new invasive zone in liver cancer, providing fresh insights into how tumors invade and metastasize. By employing BGI Group's cutting-edge spatial-temporal multi-omics technology, Stereo-seq, along with single-cell sequencing technology, they uncovered potential treatment approaches for advanced liver cancer and other solid tumors. This study was published in the journal Cell Research.

In July, by using BGI’s stereo-seq technology, a team of researchers from BGI and global institutions released the world's first three-dimensional single-cell atlas of the cerebral cortex of macaques, setting a new milestone for the development of brain science and providing a new foundation for the research of brain diseases such as Alzheimer's and Parkinson's. Their research paper was published in Cell.


“Owned by All, Done by All, Shared by All”
The year 2023 marked the 20th anniversary of the completion of the Human Genome Project. To celebrate this milestone, BGI took the lead in initiating the ‘Human Spatiotemporal Omics’ project and introduced the 'Microbiome-Omics Health Axis Initiative,' or MOHA Initiative, alongside other significant international scientific endeavors.

Group photo of the participants at the 15th Anniversary of MetaHIT Project and MOHA Initiative launch ceremony.
Addressing Health Needs
BGI Group has developed a diverse array of detection products that cover reproductive health, cancer, infectious disease prevention, and chronic disease management, addressing health needs throughout the entire life cycle. These products have benefited over 30 million people to date. In the field of gene therapy, Hemogen, a subsidiary of BGI Group, has shown notable clinical success. So far, five patients with β-thalassemia and one patient with α-thalassemia have become free from the need for blood transfusions after undergoing treatment.

Genetic Testing
In 2023, BGI Group launched a suite of new genetic testing products aimed at diagnosing early-onset coronary heart disease, assessing risk for Alzheimer's disease, identifying cognitive impairment disorders, detecting neural system autoimmune antibodies, and targeting respiratory infection pathogens with PTseq™ high-throughput genetic testing. It also introduced COLOTECT, a non-invasive fecal DNA methylation test for colorectal cancer.

Gene Therapy
In 2023, Hemogen, working alongside Southern Medical University and other collaborators, completed the world's first successful gene therapy for a patient with transfusion-dependent α-thalassemia. The patient was free from transfusion dependence on the 26th day after reinfusion of the transduced autologous hematopoietic stem cells. This is the first case in the world where a patient with transfusion-dependent α-thalassemia successfully became independent of transfusion through gene therapy.

In December, Hemogen's proprietary product, HGI-001 injection, received implied license to enter clinical trials by the National Medical Products Administration (NMPA) of China. This gene therapy product, derived from autologous hematopoietic stem cells, is designed to treat patients with transfusion-dependent β-thalassemia.
Cooperation and Partnerships
In 2023, government departments or institutional organizations from nearly 40 countries, including Saudi Arabia, Hungary, Serbia, and Indonesia, conducted mutual visits with BGI Group to exchange ideas on platform construction, the medical industry development, and talent training.

International Cooperation
In 2023, BGI Group conducted mutual visits with government departments or institutions from dozens of countries.

In February, BGI Group donated a gene sequencer to the South African Medical Research Council (SAMRC).

In June, BGI Group signed a cooperation agreement with the Ministry of Environment, Water, and Agriculture (MEWA). The agreement focuses on biogenetic resource preservation, agriculture modernization, and environmental management.

In September, the Minister of Health of the Republic of Indonesia, Budi G. Sadikin, conveyed his warmest wishes to BGI Group and celebrated the organization’s 24th anniversary as a year filled with outstanding achievements and invaluable partnerships with Indonesia.

In November, Serbian Prime Minister Ana Brnabic and her delegation paid a visit to the Multi-Omics Joint Center, a collaborative endeavor between the Chinese Academy of Sciences' Institute of Genetics and Developmental Biology and BGI-Research. Prime Minister Brnabic acknowledged BGI's achievement and expressed her gratitude for BGI’s contributions to Serbia.

Voices from Partners
In March, Professor Chris Marine, Science Director at the VIB-KU Leuven Center for Cancer Biology in Belgium, and Professor Oliver Bechter, a Medical Oncologist and Professor at KU Leuven, UZ Leuven, shared their research achievements on melanoma cells using BGI Group's spatiotemporal omics technology. Professor Marine praised the technology by noting, “Breakthroughs in understanding health and disease require transformative technologies! Thanks to BGI for their continued efforts to bring innovative tools to the scientific community.

Professor Oliver Bechter (left) with Professor Chris Marine.
In August, Professor Rajeev Varshney, a Fellow of the Royal Society, Director of the Centre for Crop and Food Innovation, Director of the Western Australian State Biotechnology Centre, and International Chair in Agriculture and Food Security at Murdoch University, Australia, commented on the collaboration with BGI, noting: “One key thing with BGI Group is that they are not just a service provider. When they work with a scientist or research institute, they work as true collaborators in terms of their data analysis, in terms of their interpretation.

Professor Rajeev Varshney in a glass house at Murdoch University.
Women's Health
BGI Group provides SeqBRCA™-Breast Cancer and Ovarian Cancer Susceptibility Genes BRCA1/2 Genetic Risk Assessment, as well as BGI SENTIS™ Hereditary Cancer Screening for early detection of breast cancer and other cancer types.

In July, BGI Genomics, a subsidiary of BGI Group, achieved "Good" ratings in all assessed categories in the College of American Pathologists (CAP) BRCA-A 2023 BRCA1/2 Sequencing evaluation program at three of its medical testing laboratories located in Denmark, Shenzhen, and Tianjin. BGI has maintained the tradition of participating in the CAP PT program annually, and its laboratories located in Denmark, Australia, Hong Kong, Shenzhen, and Tianjin have consistently received a "Good" performance rating.


Perennial Rice
Perennial rice has been successfully cultivated in Africa and Southeast Asia, yielding positive outcomes in crop production. Notably, the perennial rice grown in Madagascar has achieved an average yield exceeding 10 tons per hectare, leading to significant cost reductions for the local farmers.

Local farmers in Madagascar are harvesting perennial rice.
Transforming Deserts into Fertile Farmlands
BGI Group is working to find ways to transform arid deserts into fertile farmland. In addition to converting sand into a solid soil mass to enhance its water retention capability, BGI has isolated more than 400 strains of functional bacteria. These microorganisms are integral to promoting crop growth in desert-transformed farmlands, such as those in the Ulan Buh Desert of Inner Mongolia. In these regions, sorghum yields exceed 3,600 kilograms per acre, surpassing the national average in China by 1.5 times.

Desert-transformed farmlands in the Ulan Buh Desert of
Inner Mongolia. Left:untransformed desert; right:
sunflower planting area after transformation
Talent Development
In 2023, BGI College signed strategic cooperation or joint training agreements with 35 universities or institutions in Europe and the Asia-Pacific region and launched its first large-scale international student training program, enrolling students from 10 countries or regions. And also, successfully signed 16 strategic cooperation and joint training agreements, thereby initiating the first batch of large-scale training programs for international students.

10.The international scholars' hands-on experiment simulation session in a BGI laboratory.
Advancing Global Standards
To date, BGI has been involved in proposing or contributing to 311 global standards. These standards encompass areas such as accurate diagnosis and treatment of tumors, life sciences research tools, agricultural practices, and others. BGI has received over 140 international quality system certifications and accreditations, covering aspects like laboratory operations, environmental management, occupational health, information security, and personal privacy.

In 2023, BGI participated in drafting and issuing 53 standards, comprising three international standards, two European Union standards, and eight China national standards. This effort included jointly proposing and drafting the first ISO standard for sequencing of infectious diseases and their clinical application, contributing to the first EU standard for high-throughput testing processes of human DNA/RNA, as well as the world's first international standards for metagenomic data processing.

In 2023, BGI Group obtained 117 new product certifications and 9 quality system certifications.

In September, the China National GeneBank (CNGB) Sequence Archive (CNSA) was recommended as a data-type-specific repository for genomics and functional genomics data by Cell Press.


In November, the China National GeneBank DataBase (CNGBdb) was certified as a Trustworthy Data Repository by the CoreTrustSeal Standards and Certification Board.

Intellectual Property
In 2023, BGI Group applied for 742 patents, including 132 PCT applications. Additionally, it was granted 316 patents in China and 77 patents in overseas countries. As of December 29th, 2023, BGI Group has applied for a total of 5,932 patents, including 1,028 PCT applications filed across 43 countries and regions, including China, the U.S., Europe, and Japan. And it has been granted 2,138 patents - 1,649 in China and 489 in overseas countries.

Embracing Technology for Good
Over the years, BGI has spearheaded innovation and development in the multi-omics fields with its integrated 'industry-academia-research' development model.

As of now, the Mammoth Foundation has launched several public welfare initiatives, including genetic testing for ALS (Amyotrophic Lateral Sclerosis) and precision testing for cancer prevention and treatment. In 2023, notably, the Mammoth Foundation donated nearly 400 genetic tests for ALS, aiding in the management of the disease's progression for patients.

Furthermore, Mammoth Education, a subsidiary of the Mammoth Foundation, has facilitated the creation of bioinformatics experiment courses in over 20 universities, providing essential learning resources for students interested in biology.
BGI Group is dedicated to advancing gene technology for the benefit of humanity by continuously promoting its accessibility to the public.
Copyright © All Rights Reserved 2024 BGI Group